Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
NCT ID: NCT04923802
Last Updated: 2024-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
13 participants
OBSERVATIONAL
2021-06-24
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung Cancer
NCT05928299
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
NCT05636605
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
NCT07026669
Multiomics Tumor Evolution Model of NSCLC
NCT05352035
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
NCT07057102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients in the group will be allowed to collect whole blood and tissue samples at specific time points
* Eastern Cooperative Oncology Group Performance Status of 0-1 within 28 days prior to registration
* No previous systemic anti-tumor therapy
* Signed informed consent
Exclusion Criteria
* Patients with serious mental disease
* Prior allogeneic stem cell or solid organ transplantation
* Pregnant or lactating women
* Patients who cannot obtain tumor tissue samples and / or whole blood
* Patients with history of blood transfusion within half a year
* Patients with any other malignancy diagnosed within 5 years
* Received systemic anti-tumor therapy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xinqiao Hospital of Chongqing
OTHER
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Shanghai Chest Hospital
OTHER
Wuhan University
OTHER
Renmin Hospital of Wuhan University
OTHER
Tongji Hospital
OTHER
Southwest Hospital, China
OTHER
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER
People's Hospital of Chongqing
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
The Second Affiliated Hospital of Kunming Medical University
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
The Affiliated Hospital Of Southwest Medical University
OTHER
Guizhou Provincial People's Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Shaanxi Provincial Cancer Hospital
OTHER
First Hospital of China Medical University
OTHER
Fujian Provincial Hospital
OTHER
Peking University Shenzhen Hospital
OTHER
Affiliated Cancer Hospital of Shantou University Medical College
OTHER
The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
OTHER
GeneCast Biotechnology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Zhu
Role: PRINCIPAL_INVESTIGATOR
Xinqiao Hospital of Chongqing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Affiliated Hospital of Army Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOTIVATION
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.